World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
122
Citations
82526
World Ranking
3406
National Ranking
1876

Overview

Mitchell L. Shiffman is affiliated with the Bon Secours Health System in the United States. Their research primarily focuses on hepatology within the field of medicine, with a significant emphasis on liver diseases. Shiffman's work spans several subfields including hepatology, epidemiology, surgery, pulmonary and respiratory medicine, and hematology.

Their published research has appeared most frequently in notable medical journals and venues such as the Journal of Hepatology, Hepatology, Clinics in Liver Disease, UNC Libraries, and Alimentary Pharmacology & Therapeutics.

Shiffman's research topics extensively cover various aspects of liver disease diagnosis and treatment, liver diseases and immunity, hepatitis C virus research, liver disease and transplantation, pediatric hepatobiliary diseases and treatments, gallbladder and bile duct disorders, and hepatitis B virus studies.

Frequent collaborators include Kris V. Kowdley, Christopher L. Bowlus, Robert P. Myers, Guy Neff, and Stephen A. Harrison, each of whom has coauthored multiple publications with Shiffman.

Selected recent papers authored or coauthored by Shiffman include:

  • Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials (2020), Journal of Hepatology
  • Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial (2020), Hepatology
  • Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH (2020), Hepatology
  • Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis (2023), New England Journal of Medicine
  • Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations (2020), The American Journal of Gastroenterology

Best Publications

  • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

    Michael W. Fried;Mitchell L. Shiffman;K. Rajender Reddy;Coleman Smith

  • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

    Michael P. Manns;John G. McHutchison;Stuart C. Gordon;Vinod K. Rustgi

  • Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

    John G. Mchutchison;Stuart C. Gordon;Eugene R. Schiff;Mitchell L. Shiffman

  • Nonalcoholic Steatohepatitis: Association of Insulin Resistance and Mitochondrial Abnormalities

    Arun J. Sanyal;Carol Campbell-Sargent;Faridoddin Mirshahi;William B. Rizzo

  • Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

    Patrick Marcellin;Ting Tsung Chang;Seng Gee Lim;Myron J. Tong

  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

    John G. McHutchison;Eric J. Lawitz;Mitchell L. Shiffman;Andrew J. Muir

  • Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

    Gary L. Davis;Rafael Esteban-Mur;Vinod Rustgi;John Hoefs

  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

    Kris V. Kowdley;Stuart C. Gordon;K. Rajender Reddy;Lorenzo Rossaro

  • Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

    Pouneh Mofrad;Melissa J. Contos;Mahmadul Haque;Carol Sargeant

  • Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B

    Patrick Marcellin;E Jenny Heathcote;Maria Buti;Ed Gane

  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

    Ira M. Jacobson;Stuart C. Gordon;Kris V. Kowdley;Eric M. Yoshida

  • Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

    E. J. Heathcote;M. L. Shiffman;W. G. E. Cooksley;G. M. Dusheiko

  • ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

    Fred Poordad;Christophe Hezode;Roger Trinh;Kris V. Kowdley

  • A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

    F. Nevens;P. Andreone;G. Mazzella;S. I. Strasser

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

    Karen L. Lindsay;Christian Trepo;Tobias Heintges;Mitchell L. Shiffman

  • Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

    Alexander J. Thompson;Andrew J. Muir;Andrew J. Muir;Mark S. Sulkowski;Dongliang Ge

  • Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

    Peter Ferenci;Michael W. Fried;Mitchell L. Shiffman;Coleman I. Smith

  • Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

    Mitchell L. Shiffman;Adrian M. Di Bisceglie;Karen L. Lindsay;Chihiro Morishima

  • A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C

    Peter Hayes;John Plevris

Frequent Co-Authors

Velimir A. Luketic
Velimir A. Luketic Virginia Commonwealth University
Arun J. Sanyal
Arun J. Sanyal Virginia Commonwealth University
Richard K. Sterling
Richard K. Sterling Virginia Commonwealth University
Robert A. Fisher
Robert A. Fisher Beth Israel Deaconess Medical Center
Andrew J. Muir
Andrew J. Muir Duke University
Timothy R. Morgan
Timothy R. Morgan California State University, Long Beach
Gregory T. Everson
Gregory T. Everson University of Colorado Denver
Eric Lawitz
Eric Lawitz The University of Texas at Austin
William M. Lee
William M. Lee The University of Texas Southwestern Medical Center
Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens doors to several related online degrees and career pathways in the healthcare sector. Online programs offer flexibility and affordability to suit various backgrounds and goals.

If you’re interested in the pharmaceutical field, exploring the cheapest online pharmacy school options can set you on a path toward a PharmD and pharmacy licensure without enormous debt.

For those drawn to the intersection of healthcare and technology, accredited him programs train professionals in managing patient data and overseeing medical records—a field with strong career growth.

Individuals seeking quick entry into healthcare can consider how much is medical billing and coding school to learn about managing insurance claims and reimbursements. This specialized training prepares you for immediate employment in various clinical settings.

Finally, becoming a nurse practitioner offers a rewarding and impactful career. Many students research the cheapest fnp programs online to advance their nursing practice and increase their scope of care.

These online degree options provide multiple pathways into healthcare, each with unique advantages for aspiring professionals.

Best Scientists Citing Mitchell L. Shiffman

Trending Scientists

Recently Published Articles